

# Novel Agent Improves GI Function in Pain Patients

## Alvimopan May Increase Spontaneous Bowel Movements in Patients Taking Opioids

|                    | Average Increase in SBMs per Week |
|--------------------|-----------------------------------|
| 0.5 mg twice daily | 3.5                               |
| 1 mg once daily    | 3.5                               |
| 1 mg twice daily   | 4.3                               |
| Placebo            | 1.7                               |

Note: Based on a study of 522 patients receiving opioid treatment.  
Source: Dr. Webster

BY ROXANNE NELSON  
Contributing Writer

SAN ANTONIO — Alvimopan is effective in relieving gastrointestinal adverse events associated with opioid administration, according to preliminary data.

“We were able to demonstrate that alvimopan, a  $\mu$ -opioid receptor antagonist that is taken orally, was able to increase bowel function significantly,” lead investigator Dr. Lynn Webster reported in a poster presentation at the annual meeting of the American Pain Society Meeting. “At several different dos-

es, the side effects were similar to what was seen with placebo.”

Patients using opioids to treat chronic moderate to severe pain often develop gastrointestinal adverse events, including constipation, abdominal pain and discomfort, and bloating. These side effects can prevent some patients from adequately managing their pain.

“There is a very significant need for this type of agent,” said Dr. Webster, medical director of a group practice in Salt Lake City. “About 50% of my patients have a significant bowel dysfunction from opioid use, and it sometimes limits the amount of opioids that they can be given.”

The problem can be life threatening, causing complications such as bowel perforation in some patients, he added.

The efficacy of alvimopan was evaluated in a 6-week study of 522 patients receiving opioid treatment for persistent noncancer pain. The phase IIb double-blind design randomized patients to 0.5 mg alvimopan twice daily, 1 mg alvimopan once daily, 1 mg alvimopan twice daily, or placebo.

**Overall, 40% of the patients who received alvimopan reported moderate to substantial improvement in constipation, vs. 14% with placebo.**

Patients in all of the groups reported an average frequency of one spontaneous bowel movement (SBM) per week during the baseline period. The average increase in SBMs per week during the treatment period was about

3.5 in the two daily alvimopan groups, and 4.3 in the twice daily group; the increases were significantly greater than the 1.7 increase seen among patients given placebo. (See chart.) The increase in SBMs was apparent within the first week of the study, was sustained throughout the entire treatment period, and returned toward baseline when alvimopan was discontinued.

Patients on active therapy also reported improvements in straining, stool consistency, completeness of evacuation, and abdominal pain and bloating, compared with placebo. Overall, 40% of the patients who received alvimopan reported moderate to substantial improvement in constipation, vs. 14% with placebo. Patients using alvimopan also reported a significantly lower need for rescue laxatives.

The most common adverse events reported in the trial were abdominal pain, nausea, and diarrhea, occurring in 30%-43% of patients on active therapy and 36% of those on placebo. Overall, withdrawal rates for adverse events were 13% or lower across all treatment groups. The best benefit-to-risk profile was seen with the 0.5-mg twice-daily dose.

“The important thing is that we demonstrated efficacy with a low risk of adverse events,” Dr. Webster said. “Any opportunity that we have to restore as much normal bowel function as possible, with very little side effect and risk, presents a great opportunity.”

## Improving the Care of Your Female Patient

### CLINICAL HIGHLIGHTS:

- ADHD in Women
- Bipolar Illness
- Cancer Screening
- Contraception Update
- Depression & Anxiety
- Hyperactive Bladder/Incontinence
- Hypertension & Stroke
- Infertility Update
- Management of Insomnia
- Smoking Cessation
- STIs and Abnormal Pap
- The Obesity Epidemic
- Treating Chronic Pain
- Type II Diabetes
- Women's Sexuality



## PERSPECTIVES IN WOMEN'S HEALTH

November 10-12, 2006  
The Palace Hotel • San Francisco

Presented by:

Ob.Gyn. News • Family Practice News  
Clinical Psychiatry News • Internal Medicine News

This educational conference focuses on the conditions and diseases that may be unique to women, are more prevalent in women, or manifest differently in women. A multidisciplinary faculty addresses prevention, symptoms, diagnosis, and treatment strategies with emphasis on the complete and unique needs of the female patient.

### Program Chair:

**Anita L. Nelson, MD**  
David Geffen School of Medicine at UCLA/  
UCLA Medical Center


### Co-Chairs:

**Sidney Goldstein, MD**  
Case Western Reserve University  
School of Medicine/Henry Ford  
Hospital

**Paul S. Jellinger, MD, MACE**  
University of Miami

**Charles E. Miller, MD, FACOG**  
University of Illinois at Chicago/University of Chicago

**E. Albert Reece, MD, PhD, MBA**  
University of Arkansas College of Medicine



Register Today at:  
[www.WomensHealthCongress.com](http://www.WomensHealthCongress.com)  
or call 888-799-2995



Perspectives in Women's Health is jointly sponsored by the Elsevier Office of Continuing Medical Education and Elsevier/International Medical News Group.

